Nitric oxide-based molecular strategies for restenosis therapy

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 5, 2005, Pages 483-495

  Lin, Chia En ^a   Janero, David R ^b   Garvey, David S ^b  

^a NitroMed Inc   (United States)

^b NONE

Author keywords

Angioplasty; Atherosclerosis; Device coating; Endothelial dysfunction; Inflammation; Nitric oxide (NO); Restenosis; Stent

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIACYLGLYCEROL DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENYLNITROSAMINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCEROL DERIVATIVE; GLYCEROPHOSPHOLIPID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOACYLGLYCEROL; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PACLITAXEL; POLYMER; RAPAMYCIN; SPHINGOSINE DERIVATIVE; STEROL DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD VESSEL FUNCTION; BRACHYTHERAPY; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; HOMEOSTASIS; HUMAN; MATERIAL COATING; MOLECULAR BIOLOGY; MOLECULAR WEIGHT; NONHUMAN; PATENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSTHESIS; RESTENOSIS; REVIEW; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR DISEASE; VASCULAR PATENCY;

EID: 19044369364     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.5.483     Document Type: Review

References (70)

1. ROSS R, GLOMSET J: The pathogenesis of atherosclerosis. N. Engl. J. Med. (1976) 295:369-377.
2. ORFORD JL, SELWYN AP. GANZ P et al.: The comparative pathobiology of atherosclerosis and restenosis. Am. J. Cardiol. (2000) 86:6H-11H.
3. ELLIS SG: Interventions in acute myocardial infarction. Circulation (1990) 81:IV43-IV50.
4. ARJOMAND H, TURI ZG, MCCORMICK D et al.: Percutaneous coronary intervention: historical perspectives, current status, and future directions. Am. Heart. J. (2003) 146:787-796.
5. KHALIL AA: Catheter-based treatment of atherosclerosis, options for effective percutaneous intervention are plentiful. Postgrad. Med. (2004) 115:14-25.
6. MOSES JW, CARLIER S. MOUSSA I: Lesion preparation prior to stenting. Rev. Cardiovasc. Med. (2004) 5:S16-S21.
7. DETRE K, HOLUBKOV R, YEH W et al.: Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981: the NHLBI registry. N. Engl. J. Med. (1988) 318:265-270.
8. SCHWARTZ RS, HENRY TD: Pathophysiology of coronary artery restenosis. Rev. Cardiovasc. Med. (2002) 3:S4-S9
9. RAJAGOPAL V, ROCKSON SG: Coronary restenosis: a review of mechanisms and management. Am. J. Med. (2003) 115:547-553.
10. BEYAR R: Novel approaches to reduce restenosis. Ann. NY Acad Sci. (2004) 1015:367-378.
11. SCHIELE TM, KROTZ F, KLAUSS V: Vascular restenosis: striving for therapy. Expert Opin. Pharmacother. (2004) 5:2221-2232.
12. ROSANIO S, TOCCHI M, PATTERSON C et al.: Prevention of restenosis after percutaneous interventions: the medical approach. Thromb. Haemost. (2000) 82:164-170.
13. LEVINE GN, KERN MJ, BERGER PB et al.: Management of patients undergoing percutaneous coronary revascularization. Ann. Int. Med. (2003) 139:123-136.
14. LAU KW, MAK KH, HUNG JS et al.: Clinical impact of stent construction and design in percutaneous coroanry intervention. Am. Heart J. (2004) 147:764-773.
15. BARBATO E, MARCO J, WIJNS W: Direct stenting. Eur. Heart J. (2004) 24:304-403.
16. SIEGWART U, PUEL J, MIRKOVITCH V et al: Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N. Eng. J. Med. (1987) 316:701-706.
17. DUNDAR Y, HILL RA, BAKHAI A et al.: Angioplasty and stents in coronary artery disease: a systematic review and meta-analysis. Scand. Cardiovasc. J. (2004) 38:200-210.
18. SCHWARTZ RS, CHRONOS NA, VIRMANI R: Preclinical restenosis models and drug-eluting stents. J. Am. Coll. Cardiol. (2004) 44:1373-1385.
19. WELT FG, ROGERS C: Inflammation and restenosis in the stent era. Arterioscler. Thromb. Vasc. Biol. (2002) 22:1769-1776.
20. INDOLFI C, MONGIARDO A, CURCIO A et al.: Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. Trends Cardiovasc. Med. (2003) 13:142-148.
21. FROESCHL M, OLSEN S, MA X et al.: Current understanding of in-stent restenosis and the potential benefit of drug eluting stents. Curr. Drug Targets Cardiovasc. Haematol. Disord. (2004) 4:103-117.
22. SERRUYS PW, STRAUSS BH, BEATT KJ et al.: Angiographic follow-up after the placement of coronary-artery stents. N. Engl. J. Med. (1996) 334:1084-1089.
23. VETROVEC GW: Optimizing percutaneous coronary intervention outcomes. The next steps. Circulation (2005) 111:125-126.
24. SINDERMANN JR, VERIN V, HOPEWELL JW et al.: Biological aspects of radiation and drug-eluting stents for the prevention of restenosis. Cardiovasc. Res. (2004) 63:22-30.
25. HARGAVA B, KARTHIKEYAN G, TRIPURANENI P: Intravascular brachytherapy: indications and management of adverse events. Am. J. Cardiovasc. Drugs 4:385-394.
26. KALUZA GL, RAINZER AE: Brachytherapy for restenosis after stenting for coronary artery disease: its role in the drug-eluting stent era. Curr. Opin. Cardiol. 19:601-607.
27. LAU KW, JOHAN A, SIGWART U et al.: A stent is not just a stent: stent construction and design do matter in its clinical performance. Singapore Med. J. (2004) 45:305-312.
28. ETTENSON DS. EDELMAN ER: Local drug delivery: an emerging approach in the treatment of restenosis. Vasc. Med. (2000) 5:97-102.
29. CHENG-LAI A, FRISHMAN WH: Sirolimus-eluting coronary stents: novel devices for the management of coronary artery disease. Am. J. Therapeut. (2004) 11:218-228.
30. SONODA S, HONDA Y, KATAOKA T et al.: Taxol-based eluting stents-from theory to human validation: clinical and intravascular ultrasound observations. J. Invas. Cardiol. (2003) 15:109-114.
31. HILL RA, DUNDAR Y, BAKHAI A et al.: Drug-eluting stents: an early systematic review to inform policy. Eur. Heart J. (2004) 25:902-919.
32. SCHOFER J, BODE C, SILBER S: Drug-eluting stents for in-stent restenosis and acute myocardial infarction. Herz (2004) 29:195-200.
33. WOODS TC, MARKS AR: Drug-eluting Stents. Ann. Rev. Med. (2004) 55:169-178.
34. VIRMANI R, KOLODGIE FD, FARB A et al.: Drug eluting stents: are human and animal studies comparable? Heart (2003) 89:133-138.
35. BHATIA V, BHATIA R, DHINDSA M: Drug-eluting Stents: new era and new concerns. Postgrad. Med. J. (2004) 80:13-18.
36. JANERO DR, EWING JF: Nitric oxide and postangioplasty restenosis: pathological correlates and therapeutic potential. Free Radic. Biol. Med. (2000) 29:1199-1221.
37. RUBIO AR, MORALES-SEGURA MA: Nitric oxide, an iceberg in cardiovascular physiology: far beyond vessel tone control. Arch. Med. Res. (2004) 35:1-11.
38. RAGHAVAN SAV, DIKSHIT M: Vascular regulation by the L-arginine metabolites, nitric oxide and agmatine. Pharmacol. Res. (2004) 49:397-414.
39. LANDMESSER U, HORNIG B, DREXLER H: Endothelial function. A critical determinant in atherosclerosis? Circulation (2004) 109:II27-II33.
40. HIGASHI Y, YOSHIZUMI M: New methods to evaluate endothelial function: method for assessing endothelial function in humans using a strain-gauge plethysmography: nitric-oxide dependent and -independent vasodilation. J. Pharmacol. Sci. (2003) 93:399-404.
41. GOMMA AH, ELRAYESS MA, KNIGHT CJ et al.: The endothelial nitric oxide synthase (Glu298Asp and -786T > C) gene polymorphisms are associated with coronary in-stent restenosis. Eur. Heart J. (2002) 23:1955-1962.
42. GORCHAKOVA O, KOCH W, VON BECKERATH N et al.: Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement. Eur. Heart J. (2003) 24:820-827.
43. PIATTI P, DI MARIO C, MONTI LD et al.: Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation (2003) 108:2074-2081.
44. WYKRETOWICZ A, DZIARMAGA M, SZCZEPANIK A et al.: Prospective evaluation of hydroperoxide plasma levels and stable nitric oxide end products in patients subjected to angiography for coronary artery disease. Int. J. Cardiol. (2003) 89:173-178.
45. KLPSHIDZE N, KEELAN MH, PETERSEN JR et al.: Photoactivation of vascular iNOS and elevation of cGMP in vivo: possible mechanism for photovasorelaxation and inhibition of restenosis in an atherosclerotic rabbit model. Photochem. Photobiol. (2000) 72:579-582.
46. BUERGLER JM, TIL FO, SCHULZ DG et al.: Use of nitric oxide-eluting polymercoated coronary stents for prevention of restenosis in pigs. Coron. Artery Dis. (2000) 11:351-357.
47. AIZAWA Y, KAWABE J, HASEBE N et al.: Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation (2001) 104:455-460.
48. MAFFIA P, IANARO A, SORRENTINO R et al.: Beneficial effects of no-releasing derivative of flurbiprofen (HCT-1026) in rat model of vascular injury and restenosis. Arteriosclero. Thromb. Vasc. Biol. (2002) 22:263-267.
49. KALINOWSKI M, ALFKE H, BERGEN S et al.: Comparative trial of local pharmacotherapy with L-arginine, r-hirudin, and molsidomine to reduce restenosis after balloon angioplasty of stenotic rabbit iliac arteries. Radiology (2001) 219:716-723.
50. NAPOLI C, ALDINI G, WALLACE JL et al.: Efficacy and age-related effects of nitric oxide-releasing aspirin on exprimental restenosis. Proc. Natl. Acad. Sci. USA (2002) 99:1689-1694.
51. BAEK SH, HRABIE JA, KEEFER LK et al.: Augmentation of intraperitoneal nitric oxide level by a prolonged-release nitric oxide donor reduces luminal narrowing after porcine coronary angioplasty. Circulation (2002) 105:2779-2784.
52. INDOLFI C, TORELLA D, COPPOLA C et al.: Physical training increases eNOS vascular expression and activity and reduces restenosis after balloon angioplasty or arterial stenting in rats. Circ. Res. (2002) 91:1190-1197.
53. ROLLAND PH, MEKKAOUIO C, PALASSI et al.: Efficacy of local molsidomine delivery from a hydrogelcoated angioplasty balloon catheter in the atherosclerotic porcine model. Cardiovasc. Intervent. Radiol. (2002) 20:65-72.
54. ROLLAND PH, BARTOLI JM, PIQUET P et al.: Local delivery of NO-donor molsidomine post-PTCA improves haemodynamics, wall mechanics and histomorphometry in atherosclerotic porcine SFA. Eur. J. Endovasc. Surg. (2002) 23:226-233.
55. WANG K, KESSLER PD, ZHOU Z et al.: Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model. Mol. Ther. (2003) 7:597-603.
56. HARNEK J, ZOUCAS E, SJUVE R et al.: Local infusion of the nitric oxide donor sin-1 after angioplasty. Effects on intimal hyperplasia in porcine coronary arteries. Acta Radiologica 44:395-402.
57. DO YS, KAO EY, GANAHA F et al.: In-stent restenosis limitation with stent-based controlled-release nitric oxide: initial results in rabbits. Radiology 230:377-382.
58. LIN C-E, GARVEY DS, JANERO DR et al.: Combination of paclitaxel and nitric oxide as a novel treatment for the reduction of restenosis. J. Med. Chem. (2004) 47:2276-2282.
59. WÖHRLE J, HÖHER M, NUSSER T et al.: No effect of highly dosed nitric oxide donor molsidomine on the angiographic restenosis rate after percutaneous coronary angioplasty: a randomized, placebo controlled, double-blind trial. Can. J. Cardiol. 19:495-500.
60. JANERO DR: Nitric oxide (NO)-related pharmaceuticals: contemporary approaches to therapeutic NO modulation. Free Radic. Biol. Med. (2000) 28:1495-1506.
61. BARBATO JE, TZENG E: Nitric oxide and arterial disease. J. Vasc. Surg. (2004) 40:187-193.
62. WANG PG, XIAN M, TANG X et al.: Nitric oxide donors: chemical activities and biological applications. Chem. Rev. (2002) 102(4):1091-1134.
63. JANERO DR, BRYAN NS, SAIJO F et al.: Differential nitros(yl)ation of blood and tissue constituents during glyceryl trinitrate biotransformation in vivo. Proc. Natl. Acad. Sci. USA (2004) 101:16958-16963.
64. GRUCHALA M, ROY H, BHARDWAJ S et al.: Gene therapy for cardiovascular diseases. Curr. Pharm. Des. (2004) 10:407-423.
65. KOPP CW, DE MARTIN R: Gene therapy for the prevention of restenosis. Curr. Vasc. Pharmacol. (2004) 2:183-189.
66. SCHURMANN K, VORWERK D, BUCKER A et al.: Perigraft inflammation due to Dacron-covered stent-grafts in sheep iliac arteries: correlation of MR imaging and histopathologic findings. Radiology (1997) 204(3):757-763.
67. OTAL P, ROUSSEAU H, VINEL JP et al.: High occlusion rate in experimental transjugular intrahepatic portosystemic shunt created with a dacron-covered nitinol stent. J. Vasc. Interv. Radiol. (1999) 10(2 Pt. 1):183-188.
68. GOODWIN SC, YOON HC, CHEN G et al.: Intense inflammatory reaction to heparin polymer coated intravascular palmaz stents in porcine arteries compared to uncoated palmaz stents. Cardiovasc. Intervenr Radiol. (2003) 26(2):158-167.
69. VIRMANI R, LIISTRO F, STANKOVIC G et al.: Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. (2002) 106(21):2649-2651.
70. VAN DER HOEVEN BL, PIRES NM, WARDA HM et al.: Drug-eluting stents: results, proimises and problems. Int. J. Cardiol. (2005) 99:9-17.